Royalty and Commercial Payment Purchase Agreements - Palo (Details) |
12 Months Ended | |||
|---|---|---|---|---|
|
Sep. 26, 2019
USD ($)
|
Dec. 31, 2022
USD ($)
|
Dec. 31, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
|
|
| Agreements | ||||
| Long-term royalty and commercial payment receivables | $ 63,683,000 | $ 69,075,000 | $ 34,575,000 | |
| Impairment of long-term royalty receivable | 0 | $ 0 | ||
| Palo | Royalty Purchase Agreement | ||||
| Agreements | ||||
| Number of drug candidates | 6 | |||
| Payments related to purchase of royalty rights and other commercial payment rights | $ 10,000,000.0 | |||
| Long-term royalty and commercial payment receivables | $ 10,000,000.0 | |||
| Impairment of long-term royalty receivable | $ 0 | |||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Number of drug candidates under the terms of the agreement. No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets. No definition available.
|
| X | ||||||||||
- Definition Long-term royalty and commercial rights receivables, non current. No definition available.
|
| X | ||||||||||
- Definition Payments related to purchase of royalty rights and other commercial payment rights. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|